Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NY:AZN)

188.90 +3.22 (+1.73%)
Streaming Delayed Price Updated: 10:52 AM EDT, Jun 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 Next >
News headline image
AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care
From AstraZeneca
Via Business Wire
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Targets Next Wave of DNA Damage Response Cancer Therapies
Via Investor Brand Network
Topics Artificial Intelligence
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
Via Investor Brand Network
AstraZeneca (NYSE:AZN) Passes the Caviar Cruise Quality Screen with Strong Profitability and Growth ↗
Via Chartmill
News headline image
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
From AstraZeneca
Via Business Wire
News headline image
IXUS vs. IEFA: Which International ETF Is Better for Most Investors? ↗
When buying international ETFs, owning more stocks in more countries might be a better bet. 
Via The Motley Fool
Topics ETFs
News headline image
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
From AstraZeneca
Via Business Wire
News headline image
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
From AstraZeneca
Via Business Wire
News headline image
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
From AstraZeneca
Via Business Wire
News headline image
Marathon Halves Its Copa Stake—The Panama Hub Advantage Still Stands ↗
Panama-based Copa Holdings operates a major airline network across the Americas, serving both passenger and cargo markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
From AstraZeneca
Via Business Wire
News headline image
3 International ETFs for Investors Looking Beyond U.S. Stocks ↗
These three international ETFs offer diversification and surprisingly strong dividends -- with the same low expense ratio of 0.07%. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade ↗
With U.S. federal debt exceeding 100% of GDP, VXUS and IXUS offer investors international equity exposure as a hedge against rising sovereign risk. 
Via MarketBeat
Topics Credit Cards ETFs Economy
News headline image
BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
From AstraZeneca
Via Business Wire
News headline image
M&G Shaved 2.4% of Methanex After a Near-Doubling ↗
Methanex supplies methanol worldwide, using integrated operations and its own fleet to serve industrial clients across major global markets. 
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer
From AstraZeneca
Via Business Wire
News headline image
Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial
From AstraZeneca
Via Business Wire
News headline image
This Low-Cost ETF Holds Almost 8,800 Stocks Across Both Developed and Emerging Markets. Here's Why It's a Compelling Long-Term Core Holding ↗
If you're looking for diversification and value, here's a good ETF to check out. 
Via The Motley Fool
Topics ETFs
News headline image
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat ↗
Via MarketBeat
News headline image
TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca results: Q1 2026
From AstraZeneca
Via Business Wire
News headline image
BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older
From AstraZeneca
Via Business Wire
News headline image
SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus
From AstraZeneca
Via Business Wire
News headline image
Is Bristol Myers Squibb the Best Bargain in Big Pharma? ↗
This pharma stock is cheap for a reason. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD
From AstraZeneca
Via Business Wire
News headline image
Pictet Loads Up MercadoLibre With 3,500 Shares Worth $6.8 Million ↗
MercadoLibre powers e-commerce, payments, and logistics for millions in Latin America with its integrated digital platform. 
Via The Motley Fool
News headline image
Could AbbVie Crash Lilly's Weight‑Loss Party? ↗
AbbVie is making progress in this market, but it is still far behind the leader. 
Via The Motley Fool
News headline image
Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity
In a move that signals a transformative shift from a clinical-stage biotech to a commercial-market leader, Ascendis Pharma (NASDAQ: ASND) officially launched its third major product, YUVIWEL... 
Via MarketMinute
Topics Economy
News headline image
Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis
In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total... 
Via MarketMinute
Topics Bonds
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.